On January 16, the UNITED STATES planned 211 million dollars (M$) for the development of a vaccine against the virus bird flu in humans. In a communiqué from January 17, US Department of Health announcement finally grant $590 million to the company Modern for the development of these vaccines. Known for the development of vaccines against the virus COVID-19the American biotechnology company is responsible here for developing messenger RNA vaccines (mRNA) against virus H5N1 of the bird flu. This funding is in addition to the $306 million released by the United States at the beginning of January for protect Americans of avian flu. Meanwhile, on January 6, a patient 65 years old is deceased after contracting the disease avian flu.
Read also: Avian flu: first human death in the United States
“MRNA technology will complement existing vaccine technology”
The ministry’s Assistant Secretary for Preparedness and Response Dawn O’Connell said in the statement that the mRNA technology “will complement existing vaccine technology, allowing us to move faster and better target emerging viruses to protect Americans from future pandemics. » In its press release, the American Department of Health assures that the $590 million will allow Moderna “ to accelerate the development of an mRNA vaccine” against flu H5N1making sure to correspond to “the strains Currently in circulation among the cows and the birds “. But this funding will also be used to extend the data around the use of mRNA vaccines to UNITED STATESuseful “if others flu strains emerge with a pandemic potential », Explains the ministry.
-Read also: Avian flu: WHO calls for strengthening surveillance of the virus in poultry, pigs and dairy cows
Health
